Preclinical studies indicate that an IDO-specific peptide vaccine (IDO vaccine) significantly inhibits tumor progression and prolongs survival in both IDO-secreting (B16F10 melanoma) and non-IDO-secreting (TC-1) murine models, highlighting its therapeutic potential regardless of baseline IDO expression (58). Here, IDO1 is linked to melanoma.